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Systems proteomic analysis reveals that clusterin and tissue inhibitor of metalloproteinases 3
increase in leptomeningeal arteries affected by cerebral amyloid angiopathy
Aims: Amyloid beta (Ab) accumulation in the walls of
leptomeningeal arteries as cerebral amyloid angiopathy
(CAA) is a major feature of Alzheimer’s disease. In this
study, we used global quantitative proteomic analysis to
examine the hypothesis that the leptomeningeal arteries
derived from patients with CAA have a distinct endophe-
notypic profile compared to those from young and elderly
controls. Methods: Freshly dissected leptomeningeal
arteries from the Newcastle Brain Tissue Resource and
Edinburgh Sudden Death Brain Bank from seven elderly
(82.9  7.5 years) females with severe capillary and
arterial CAA, as well as seven elderly (88.3  8.6 years)
and five young (45.4  3.9 years) females without CAA
were used in this study. Arteries from four patients with
CAA, two young and two elderly controls were individu-
ally analysed using quantitative proteomics. Key pro-
teomic findings were then validated using
immunohistochemistry. Results: Bioinformatics interpre-
tation of the results showed a significant enrichment of
the immune response/classical complement and extra-
cellular matrix remodelling pathways (P < 0.05) in
arteries affected by CAA vs. those from young and elderly
controls. Clusterin (apolipoprotein J) and tissue inhibitor
of metalloproteinases-3 (TIMP3), validated using
immunohistochemistry, were shown to co-localize with
Ab and to be up-regulated in leptomeningeal arteries
from CAA patients compared to young and elderly con-
trols. Conclusions: Global proteomic profiling of brain
leptomeningeal arteries revealed that clusterin and
TIMP3 increase in leptomeningeal arteries affected by
CAA. We propose that clusterin and TIMP3 could facili-
tate perivascular clearance and may serve as novel can-
didate therapeutic targets for CAA.
Keywords: clusterin, complement pathway, extracellularmatrix remodelling, leptomeningeal arteries, proteomics, TIMP3
Introduction
The deposition of amyloid-b (Ab) peptides in the walls
of cerebral arteries as cerebral amyloid angiopathy
(CAA) is a major feature of Alzheimer’s disease and
may contribute to cognitive decline [1,2]. CAA
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predominantly affects the leptomeningeal and cortical
arteries especially in the occipital lobe, while capillar-
ies are less frequently and veins rarely involved [3–5].
In the majority of cases there is no overproduction of
Ab in the vessel wall, suggesting that the deposition
of Ab in the walls of cerebral arteries is a result of a
failure of elimination of neuronally derived Ab [6].
Increasing age and possession of at least one apolipopro-
tein e4 (APOE4) allele are risk factors for CAA and both
have been suggested to impair cerebral Ab clearance sys-
tems, thereby reducing Ab elimination from the brain
[7–10]. We have demonstrated that Ab and other
solutes are eliminated along the basement membranes of
capillaries and arteries, effectively the lymphatic drai-
nage of the brain [11]. Experimental work involving
intraparenchymal injections of tracers demonstrated
that the biochemical structure and morphology of the
basement membranes of capillaries and arteries change
with age and with possession of APOE4 genotype, result-
ing in failure of efficient clearance of Ab [12–14]. The
exact targets for the facilitation of perivascular clearance
of Ab are not clear.
Proteomics allows the in-depth and global assess-
ment of gene products at the protein level as they
occur in a variety of biological specimens, including
cell lines, tissue, blood and proximal fluids. The
advanced use of liquid chromatography combined with
mass spectrometry permits the identification of thou-
sands of proteins with ultra-high precision and sensitiv-
ity, not available by any other analytical approach.
Using stable isotope isobaric reagents allow such pro-
teomes to be profiled in parallel across multiple biologi-
cal or clinical states under identical analytical
conditions, a feature referred to as the multiplex advan-
tage [15–23]. For example, such a strategy allows the
comparison of a given in vitro or in vivo model under a
given homeostatic state (that is physiological condition)
relative to a perturbation state (that is pathological
condition or exposure to a stimulus) under exactly the
same experimental conditions.
This study employed isobaric quantitative proteomic
analysis of fresh frozen human leptomeningeal arteries
from young and elderly subjects and patients with CAA
to test the hypothesis that leptomeningeal arteries
derived from patients with CAA have a unique
endophenotypic profile compared to those from young
and elderly controls.
Materials and methods
Isolation of human leptomeningeal arteries
Human fresh frozen post mortem leptomeningeal arter-
ies from the Newcastle Brain Tissue Resource and
MRC Sudden Death Brain & Tissue Bank (Edinburgh)
were used for this study. CAA cases were diagnosed
post mortem by JA, according to published criteria
including the neuritic Braak stages [24], Thal amyloid
phases [25], CERAD scores [26], NIA-AA scores [27]
and McKeith criteria [28] and showed varying degrees
of Alzheimer’s disease pathology. For CAA we used a
recently developed staging system, which assesses
meningeal and parenchymal CAA separately and also
scores capillary CAA [1,2]. All CAA cases had severe
CAA as they showed widespread circumferential Ab in
meningeal and cortical arterial vessels as well as Ab
depositions in capillary walls. None of the cases was
diagnosed with CAA during their lifetime. The cases
from the MRC Sudden Death Brain & Tissue Bank
(Edinburgh) had no neurological disease during life
and no significant neuropathological changes post
mortem. We excluded cases with arteriolosclerosis/lipo-
hyalinosis from this cohort. Samples were collected
and prepared in accordance with the National
Research Ethics Service-approved protocols. Lep-
tomeningeal arteries in the occipital regions were
removed from the frozen coronal slices from brains of
young females (45.4  3.9 years; n = 5), elderly
females without CAA (88.3  8.6 years; n = 7) and
females with severe CAA (82.6  7.5 years; n = 7)
(Table 1). Only female subjects were included in the
present study as it has been shown that sex-dependent
differences exist in CAA [29–31]. The frozen coronal
slices were placed at 20°C overnight to acclimatize
from the 70°C storage prior to dissection in a cold
cabinet at 12°C. Arteries were identified based on
their morphology of a vessel and they were distin-
guished from veins by the thicker wall and lep-
tomeningeal sheet as they penetrate the cortex. The
abundant presence of vascular smooth muscle actin
confirmed they were arteries. Selected vessels were
eased with a micro-scalpel from the meningeal surface
of the gyri and sulci, removed and placed in pre-
cooled tubes to avoid thawing. These specimens were
then snap frozen at 80°C.
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Quantitative proteomic analysis on human
leptomeningeal arteries
For the proteomic analysis, samples from two young and
two elderly subjects and four patients with CAA were
randomly selected from the cohort (Table 1). The justifi-
cation for this number of CAA cases was to compensate
for their innate tissue heterogeneity and to ensure a sta-
tistical power of over 0.7, factoring in a representative
30% measurement error and a fold change >1.5 between
replicate observations, as reported in a recent simulation
study [32]. Samples were dissolved in dissolution buffer
(0.5 M triethylammonium bicarbonate/0.05% sodium
dodecyl sulphate), homogenized using the FastPrep sys-
tem (Savant Bio, Cedex, Fr) and then subjected to pulsed
probe sonication (Misonix, Farmingdale, NY, USA).
Lysates were centrifuged (16 000 g, 10 min, 4°C) and
supernatants were measured for protein content using
the Direct DetectTM Spectroscopy system (Merck Millipore,
Darmstadt, Germany) according to the manufacturer’s
instructions. From each lysate volume (adjusted to the
highest volume of 40 ll) containing 100 lg final protein
content was subjected to reduction, alkylation, trypsin
proteolysis and eight-plex isobaric tag for relative and
absolute quantitation (iTRAQ AbSciex, San Hose, CA,
USA) labelling per supplier’s specifications (ABSciex, San
Hose, CA, USA). Labelled peptides were pooled and frac-
tionated with high-pH reversed-phase (RP) chromatog-
raphy using the Waters, XBridge C8 column
(150 9 3 mm, 3.5 lm particle) with the Shimadzu LC-
20AD HPLC (Shimadzu, Kyoto, Japan). Each resulting
fraction was LC-MS analysed with low-pH RP capillary
chromatography (PepMap C18, 50 lm ID 9 50 cm L,
100 A pore, 3.5 lm particle) and nanospray ionization
FT-MS (Ultimate 3000 UHPLC – LTQ-Velos Pro Orbitrap
Elite, Thermo Scientific, Bremen, DE) as reported previ-
ously [19,20,23] (Figure 1a).
Unprocessed raw files were submitted to Proteome
Discoverer 1.4 for target decoy searching with
SequestHT for tryptic peptides as reported by the
authors [19,20,23]. Quantification ratios were normal-
ized on the median value and log2 transformed. A pro-
tein was considered modulated in leptomeningeal
arteries from elderly subjects vs. young controls or
those affected by CAA type 1 relative to these from
young and elderly controls when its log2 ratio was
above or below 1 SD across all analysed samples per
category as reported previously [23].
Hierarchical clustering analysis visualized in heat-
map format was generated using Gene Cluster (version
3.0) and Java Treeview (version 1.1.6r4). MetaCore
(GeneGo, St. Joseph, MI, USA) and DAVID
(http://david.abcc.ncifcrf.gov) were applied to identify
prebuilt processed networks and gene ontology terms
over-represented in the modulated proteome. False dis-
covery rate (FDR) and Fisher’s exact corrected P-values
≤0.05 were considered significant.
Immunohistochemistry
The immunochemistry validation of key proteomic find-
ings was performed in all 19 subjects (young female con-
trols: n = 5, elderly female controls: n = 7, females with
CAA type 1: n = 7). Three sections of occipital cortex
from each of the cases were immunostained. After
dewaxing in xylene and rehydration through graded
alcohols, antigen retrieval was performed by immersing
slides in citrate buffer, microwaving on medium power
for 25 min and subsequently cooling. This was followed
by incubation in pepsin for 5 min (1 mg/ml 0.2 M HCl).
The tissue was blocked in 3% H2O2 and 15% goat
serum. Occipital cortex from each of the cases was incu-
bated in clusterin (Abcam: Cambridge, UK, ab42673,
rabbit polyclonal, dilution 1:500), or tissue inhibitor of
metalloproteinases 3 (TIMP3) (Abcam, Ab93637, rabbit
polyclonal, dilution 1:100) overnight at 4°C followed by
biotinylated goat anti-rabbit antibodies (Vector BA1000
dilution 1:200) and ABC peroxidase enzyme complex
(Vector PK4000, dilution 1:500). Reaction was detected
using diaminobenzidine with glucose oxidase enhance-
ment. Images were captured an Olympus: Southend-on-
Sea, Essex, UK, BX51 microscope fitted with Olympus
CC-12 colour microscope camera.
Double immunofluorescence was performed for Ab
and TIMP3. Prior to the antigen retrieval previously
described, pre-treatment was required which consisted
of 5 min in formic acid at 37°C. Tissue was blocked in
15% goat serum followed by incubation in primary
antibodies overnight at 4°C. Ab was detected using
mouse monoclonal anti-Ab IgG2b Clone 4G8, antibody
(BioLegend: London, UK, 800701; dilution 1:100). The
secondary antibody for Ab was goat anti-mouse IgG2b,
AlexaFluor 647 (A-21242), and for TIMP 3 and clus-
terin was goat anti-rabbit IgG AlexaFluor 594 (A-
27096). These were obtained from Thermo Fisher Sci-
entific and dilution 1:200. Images were captured and
© 2016 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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examined with a Leica SP8 confocal microscope. The
specificity of the immunohistochemistry staining was
confirmed by omitting the primary antibody.
Results
Quantitative proteomic analysis
The proteomic analysis resulted in the profiling of
5957 proteins (peptide FDR confidence ≥ 99%)
(Table S1). A total of 1364 proteins were differentially
expressed in arteries from elderly relative to young
subjects (Table S2), 280 in arteries from CAA cases rel-
ative to young controls (Table S3) and another 983 in
arteries from CAA cases relative to elderly controls
(Table S4). The hierarchical clustering analysis of dif-
ferentially expressed proteins between groups revealed
that leptomeningeal arteries derived from CAA patients
compared to those from young and elderly controls had
a distinct proteomic profile from arteries derived from
elderly compared to young subjects (Figure 1b).
In silico bioinformatics analysis showed that the im-
mune response/classical complement pathway (P = 5.0E-
11; 5.007E-2; 1.168E-10 in elderly vs. young controls;
Figure 1. (a) Experimental pipeline of proteomics experiment. (b) Heatmap of differentially expressed proteins in leptomeningeal arteries
of elderly controls compared to young controls, cerebral amyloid angiopathy (CAA) patients compared to young controls and CAA
patients compared to elderly controls.
© 2016 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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CAA vs. young controls; CAA vs. elderly controls
respectively) (Figure 2) and extracellular matrix remod-
elling (P = 3.3E-8; 6.349E-6; 2.317E-8 in elderly vs.
young controls; CAA vs. young controls; CAA vs.
elderly controls respectively) (Figure 3) were signifi-
cantly over-represented processes. For both pathways,
the expression levels of most proteins were found to
decrease in arteries from elderly vs. young controls,
whereas they increased in arteries from CAA patients
compared to young and elderly controls.
The expression of clusterin (apolipoprotein J) and
TIMP3 from the immune response/classical comple-
ment and the extracellular matrix remodelling path-
ways, respectively, were up-regulated in arteries from
patients with CAA compared to both young and
elderly controls [clusterin: iTRAQ mean log2 ratio
(SD) = 2.30 (0.45) and 2.87 (0.44) in CAA vs. young
and CAA vs. elderly controls respectively] [TIMP3:
iTRAQ mean log2 ratio (SD) = 1.63 (0.89) and 2.48
(0.90) in CAA vs. young and CAA vs. elderly controls
respectively].
Immunohistochemistry
Clusterin was found to co-localize with Ab in the occip-
ital cortex of CAA cases, but not in the young or
elderly controls (Figure 4). The pattern of expression
for the immunocytochemistry of TIMP3 was weak in
arteries from young controls, increased in elderly
controls and was strong in CAA patients (Figure 5).
TIMP3 and clusterin were found to co-localize with Ab
in the leptomeningeal vessels of the occipital cortex
from CAA cases (Figure 6).
Discussion
Our study showed that the global endophenotypic pro-
file of leptomeningeal arteries from elderly female
patients with severe CAA was different from that of
age-matched and young controls. The immune
response/classical complement and extracellular matrix
remodelling pathways were significantly enriched in
the differentially expressed proteome of arteries between
patients with CAA compared to young and elderly con-
trols. Most proteins participating in these pathways
were up-regulated in leptomeningeal arteries from
patients with CAA compared to these from controls,
possibly reflecting a pro-inflammatory response in
arteries affected by CAA, which could have in turn
triggered tissue remodelling processes. The inflamma-
tory profile of CAA is well characterized [33,34] and
previous studies have described an increased activation
of the complement system in cerebral amyloid plaques
as well as deposition of complement components in
CAA affected cerebral arteries [35–37]. Extracellular
matrix components can influence the deposition of Ab
thus contributing to Alzheimer’s disease progression
[38,39]. Conversely, Ab accumulation damages the
(a) (b) (c)
Figure 2. The immune response/classical complement pathway was significantly enriched in the differentially expressed proteome of
leptomeningeal arteries from elderly vs. young controls (P = 5.0E-11) (a), CAA patients compared to young controls (P = 5.007E-2) (b)
and cerebral amyloid angiopathy patients compared to elderly controls (P = 1.168E-10) (c).
© 2016 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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integrity of existing extracellular matrix, which affects
brain microvascular functions during the early stages
of Alzheimer’s disease [40–42].
The study results show that clusterin co-localizes
with Ab within the walls of leptomeningeal arteries
and its expression levels increase in leptomeningeal
(a) (b) (c)
Figure 3. The extracellular matrix remodelling pathway was significantly enriched in the differentially expressed proteome of
leptomeningeal arteries from elderly compared to young controls (P = 3.3E-8) (a), cerebral amyloid angiopathy (CAA) patients compared
to young controls (P = 6.349E-6) (b) and CAA patients compared to elderly controls (P = 2.317E-8) (c).
(a) (b) (c)
(d) (e) (f)
Figure 4. Immunohistochemistry of clusterin. DAB with haematoxylin counterstain in (a) young and (b) elderly controls and (c) cerebral
amyloid angiopathy (CAA). The intensity of immunostaining of clusterin is increased in the leptomeningeal vessels present in the sulci in
elderly control cases compared to young cases and in CAA compared to elderly control cases. Immunofluorescence for Ab and clusterin
in leptomeningeal arteries in CAA (d–e). Ab immunofluorescence (blue) in (d) is present in the whole thickness of the arterial wall in a
concentric manner; clusterin immunofluorescence (red) in (e) is also present throughout the thickness of the arterial wall; co-localization
(pink) of Ab and clusterin occupies most of the thickness of the arterial walls in (f). Scale bars: (a–c) = 100 lm/(d–f) = 50 lm.
© 2016 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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arteries from patients with CAA compared to those
from young and elderly controls. Clusterin
(apolipoprotein J or ApoJ) is a disulphide-linked het-
erodimeric glycoprotein that activates microglia, initi-
ating an inflammatory cascade [43]. Genome-wide
association studies of sporadic Alzheimer’s disease, in
which Ab accumulates both in cortical plaques and
CAA, have highlighted the importance of common
genetic variations in the gene encoding clusterin [44].
Experimental work suggests that clusterin regulates
Ab fibril formation [45] and plays a major role in the
clearance of Ab42–ApoJ complexes, via LRP2 [46–
48]. Although the predominant species of Ab in CAA
is Ab40, with progressive failure of perivascular clear-
ance of interstitial fluid, there is also accumulation of
Ab42 [49]. Clusterin appears to be sequestered with
Ab species in the vascular amyloid deposits in spo-
radic CAA, as well as in the white matter abnormali-
ties in cerebral autosomal dominant arteriopathy with
subcortical infarcts and leukoencephalopathy (CADA-
SIL) [50,51]. A recent study found a significant
positive correlation between clusterin concentration
and regional levels of insoluble Ab42 [52]. It is there-
fore possible that the up-regulation of clusterin
observed in the CAA arteries, is due to either entrap-
ment of the Ab–ApoJ complex in the perivascular
drainage pathways, or a compensatory up-regulation
of ApoJ to clear the excess Ab42 that cannot be elim-
inated normally.
In this study, we demonstrated that the expression
of TIMP3 in the brain is restricted to the walls of lep-
tomeningeal arteries and increases in CAA. Homeosta-
sis of the extracellular matrix in the brain is
maintained by the balanced action of matrix metallo-
proteinases that degrade extracellular matrix and by
tissue inhibitors of metalloproteinases (TIMP) proteins.
Human TIMP3 is a 25-kDa protein that contains
disulphide bonds and is expressed in normal central
nervous system [53]. In a study by Hoe et al. [54],
TIMP3 expression was found to increase in human
brains affected by Alzheimer’s disease (AD). Further-
more, this study showed that TIMP3 prevents a-
(a) (b) (c)
(d) (e) (f)
Figure 5. Immunohistochemistry of tissue inhibitor of metalloproteinases 3 (TIMP3) in leptomeningeal arteries. DAB with haematoxylin
counterstain in (a) young and (b) elderly controls and (c) cerebral amyloid angiopathy (CAA). The intensity of immunostaining of TIMP3
is increased in the leptomeningeal vessels present in the sulci of elderly control cases compared to young and in CAA cases compared to
elderly. Immunofluorescence for Ab and TIMP3 in leptomeningeal arteries in CAA (d–e). Ab immunofluorescence (blue) in (d) is present
in the whole thickness of the arterial wall in a concentric manner; TIMP3 immunofluorescence (red) in (e) is also present throughout the
thickness of the arterial wall; co-localization (pink) of Ab and TIMP3 occupies most of the thickness of the arterial walls, especially
concentrated in the tunica media, with less in the endothelium and outer layers of the wall (f). Scale bars: (a–c) = 100 lm/(d–
f) = 50 lm.
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cleavage of amyloid precursor protein (APP), whereas
it promotes b-cleavage of APP thus contributing to
elevated Ab levels in AD. TIMP3 preserves the integ-
rity of extracellular matrix in arteries as the absence
of TIMP3 in knock-out mice results in pathological
arterial vasodilation [55]. Our results showed that
expression of TIMP3 in the brain is restricted to the
walls of leptomeningeal, thus antagonistically target-
ing TIMP-3 could also facilitate perivascular drainage
of Ab. Examining this hypothesis was beyond the
scope of the present study and constitutes a future
objective.
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
Figure 6. Confocal microscopy images showing distribution of tissue inhibitor of metalloproteinases 3 (TIMP3) (blue) and Ab (red) in
leptomeningeal arteries from young (a–c) and elderly females (d–f) and patients with cerebral amyloid angiopathy (CAA) (g–i). Co-
localization of Ab and TIMP3 is observed in CAA, on transmission merged images (c–i). Images obtained with 920 objective. False
colour applied to channels.
© 2016 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
TIMP3 and clusterin increase in CAA affected arteries 9
In conclusion, this proteomic study demonstrates
the activation of inflammatory and extracellular
matrix remodelling pathways in human lep-
tomeningeal arteries from CAA patients compared to
these from cognitively normal young and elderly con-
trols. Furthermore, we observed increased levels of
clusterin and TIMP3 in leptomeningeal arteries from
CAA patients compared to young and elderly controls
and co-localization of these two proteins with Ab in
the occipital cortex of the CAA cases. Future work
will test the hypothesis that clusterin and TIMP3
could facilitate perivascular clearance and represent
novel therapeutic targets for CAA.
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